Systemic toxicity after isolated limb perfusion with melphalan for melanoma

European Journal of Surgical Oncology

Volumn 22, Issue 5, 1996, Pages 521-527

  Sonneveld, Eric J A ^a   Vrouenraets, Bart C ^a   Van Geel, Bert N ^b   Eggermont, Alexander M M ^b   Klaase, Joost M ^a   Nieweg, Omgo E ^a   Van Dongen, Joop A ^a   Kroon, Bin B R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Isolated limb perfusion; Melanoma; Melphalan; Systemic toxicity

Indexed keywords

ALKYLATING AGENT; MELPHALAN; TRACER;

ADOLESCENT; ADULT; AGE; AGED; ALOPECIA; ARTICLE; BONE MARROW DEPRESSION; DISEASE SEVERITY; FEMALE; FEVER; HUMAN; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; VOMITING;

EID: 0029902864     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)93085-1     Document Type: Article

References (72)

1. Creech O Jr. Krementz ET. Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporal circuit. Ann Surg 1958; 148: 616-32.
2. Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ryan RF, Creech O Jr. Regional chemotherapy for melanoma: a 35-year experience. Ann Surg 1994; 220: 520-35.
3. Coit DG. Hyperthermic isolation limb perfusion for malignant melanoma: a review. Cancer Inv 1992; 10: 277-84.
4. Hafström L, Mattsson J. Regional chemotherapy for malignant melanoma. Cancer Treat Rev 1993; 19: 17-28.
5. Bowers GJ, Copeland EM. Surgical limb perfusion for extremity melanoma. Surg Oncol 1994; 3: 91-102.
6. Rosin RD. Isolated limb perfusion. In: Kirkham N. Cotton DWU, (eds). Diagnosis and Management of Melanoma. Berlin-Heidelberg: Springer Verlag, 1992: 123-34.
7. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227-33.
8. Vrouenraets BC, Klaase JM, Van Geel AN, et al. Regional isolated limb perfusion in patients with malignant melanoma. Onkologie 1993; 16: 163-9.
9. Briele HA, Djuric M, Jung DT, Mortell T, Patel MK, Das Gupta TK. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 1985; 45: 1885-9.
10. Hafström L, Hugander A, Jönsson PE, Westling H, Ehrsson H. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma. Cancer Treat Rep 1984; 68: 867-72.
11. Scott RN, Kerr DJ, Blackie R, et al. The pharmacokinetic advantagcs of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 1992; 66: 159-66.
12. Furner RL, Brown RK. L-Phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep 1980; 64: 559-74.
13. Lee Y-TM. Loco-regional recurrent melanoma: II. Non-systemic treatments (1964-1979). Cancer Treat Rev 1988; 15: 105-33.
14. Krementz ET. Regional perfusion. Current sophistication, what next? Cancer 1986; 57: 416-32.
15. Schraffordt Koops H, Oldhoff J, Oosterhuis JW. Beekhuis H. The role of isolated limb perfusion for regional metastases of the extremities. Pigment Cell 1985; 7: 146-64.
16. McBride CM, Clark RL. Experience with L-phenylalaninc mustard dihydrochloride in isolation-perfusion of extremities for malignant melanoma. Cancer 1971; 28: 1293-6.
17. Stehlin JS, Jr, Clark RL. Melanoma of the extremities: experiences with conventional treatment and perfusion in 339 cases. Am J Surg 1965; 110: 366-83.
18. Stehlin JS Jr, Giovanella BC, De Ipolyi PD, Muenz LR, Anderson RF. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975; 140: 339-48.
19. Irvine WT, Luck RJ. Review of regional limb perfusion with melphalan for malignant melanoma. Br Med J 1966; 1: 770-4.
20. Shingleton WW. Perfusion chemotherapy for recurrent melanoma of extremity: a progress report. Ann Surg 1969; 169: 969-73.
21. Fontaine CJ, Jamieson CW. Perfusion in limb melanoma: indications and results. Proc Roy Soc Med 1974; 67: 99-100.
22. Golomb FM. Perfusion of melanoma: 133 isolated perfusions in 114 patients. Panminerva Med 1976; 18: 8-10.
23. Hansson JA, Simert G, Vang J. The effect of regional perfusion treatment on recurrent melanoma of the extremities. Acta Chir Scand 1977; 143: 33-9.
24. Jönsson PE, Hafström L. Hugander A. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities. Rec Res Cancer Res 1983; 86: 277-82.
25. Lejeune FJ, Deloof T, Ewalenko P, et al. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Rec Res Cancer Res 1983; 86: 268-76.
26. Lejeune FJ, Liénard D, El Douaihy M. Results of 206 isolated limb perfusions for malignant melanoma. Eur J Surg Oncol 1989; 15: 510-9.
27. Rege VB, Leone LA, Soderberg CH. et al. Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review. Cancer 1983; 52: 2033-9.
28. Minor DR, Allen RE, Alberts D, Peng Y-M, Tardelli G. Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55: 2638-44.
29. Fletcher JR, White CR, Fletcher WS. Improved survival rates of patients with acral lentiginous melanoma treated with hyperthermic isolation perfusion, wide excision, and regional lymphadenectomy. Am J Surg 1986; 151: 593-8.
30. Vaglini M, Santinami M, Nava M, et al. Hyperthermic antiblastic perfusion in extracorporeal circulation: surgical technique and results in the treatment of extremities' tumour. J Exiracorpor Technol 1986; 18: 12-20.
31. Krige JEJ, King HS, Strover RM. Prophylactic hyperthermic limb perfusion in stage I melanoma. Eur J Surg Oncol 1988; 14: 321-6.
32. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551-61.
33. Santinami M, Belli F, Cascinelli N, Rovini D, Vaglini M. Seven years experience with hyperthermic perfusions in extracorporal circulation for melanoma of the extremities. J Surg Oncol 1989; 42: 201-8.
34. Kettelhack Ch, Kraus Th, Hupp Th, Manner M, Schlag P. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Ear J Surg Oncol 1990; 16: 370-5.
35. Pace M. Optimization of the vascular isolation in isolated regional perfusion of the limbs. Reg Cancer Treat 1990; 3: 90-7.
36. Skene AI, Bulman AS, Williams TR, Mcirion Thomas J, Westbury G. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77: 765-7.
37. Hafström L, Rudenstam C-M, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1990; 9: 2091-4.
38. Neades GT, Evans WD, Mansel RE. Choice of agent and prediction of systemic toxicity in isolated hyperthermic limb perfusion. Reg Cancer Treat 1991; 3: 252-5.
39. Omlor G, Bahmer F, Meessen S, Zang D, Feifel G, Zaun H. Technik und Ergebnisse der hyperthermen Extremitätenperfusion bei Melanompatienten (Technique and results of isolated hyperthermic limb perfusion in malignant melanoma). Langenbecks Arch Chir 1993; 378: 21-5.
40. Rauschecker HF, Foth H, Michaelis HC, et al. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb. Cancer Chemother Pharmacol 1991; 27: 379-84.
41. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
42. Lejeune FJ, Liénard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer 1003; 29A: 606-12.
43. Vaglini M, Belli F, Ammatuna M. et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon. and melphalan. Cancer 1994; 73: 483-92.
44. Sigurdsson GH, Nachbur B, Lejeune FJ. Anesthesiologists' management of isolated limb perfusion with 'high-dose' tumor necrosis factor α. Anesthesiology 1993; 79: 1433-7
45. Kroon BBR. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 1988; 14: 101-10.
46. EORTC malignant melanoma cooperative group. Protocol 18832: a randomized trial on prophylactic isolation perfusion for stage I high risk (≥ 1.5 mm thickness) malignant melanoma of the limbs. Brussels, Belgium, 1984: 1-21.
47. Kroon BBR, Klaase JM, Van Geel AN, Eggermont AMM. Application of hyperthermia in regional isolaled perfusion for melanoma of the limbs. Reg Cancer Treat 1992; 4: 223-6.
48. Wieberdink J, Benckhuijsen C, Braat RP, Van Slooten EA, Olthius GAA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18, 905-10.
49. Benckhuijsen C, Kroon BBR, Van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157-63.
50. Stchlin JS, Clark RL, Dewey WC. Continuous monitoring of leakage during regional perfusion. Arch Surg 1961; 83: 165-71.
51. World Health Organization (WHO). WHO handbook for reporting results of cancer treatment. Geneva: WHO offset publication No. 48, 1979.
52. Klaase JM, Kroon BBR, Van Geel AN, Eggermont AMM, Franklin HR. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993; 80: 1124-6.
53. Hoekstra HJ, Naujocks T, Schraffordt Koops H, et al. Continuous leakage monitoring during hyperthermic isolaled regional perfusion of the lower limb: techniques and results. Reg Cancer Treat 1992; 4: 301-4.
54. Benckhuijsen C, Varossieau FJ, Hart AAM, Wieberdink J. Noordhoek J. Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 1986; 237: 583-8.
55. Thompson JF, Malouf DJ, Merzliakov S, Kam PCA. Efficacy - of single-dose ondansetron in the prevention of post-operative nausea and vomiting following isolated limb perfusion with cytostatic agents. Reg Cancer Treat 1993; 4: 177-82.
56. Sear JW, Roscwarme F. Anaesthesia for surgeons. In: Morris PJ, Malt RA (eds) Oxford Textbook of Surgery. New York: Oxford University Pres. 1994: 53-82.
57. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol 1992; 19 (Suppl. 15): 20-5.
58. Brown GW, Paes D, Bryson J, Freeman AJ. The effectiveness of a single intravenous dose of ondansetron. Oncology 1992; 49: 273-8.
59. Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol 1992; 3 (Suppl. 3): 47-50.
60. Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment and prevention. Anesthesiology 1992; 77: 162-84.
61. Russell D, Kenny GNC. 5-HT, antagonists in postoperative nausea and vomiting. Br J Anaesth 1992; 69 (Suppl. 1):63S-68S.
62. Slapak CA, Kufe DW. Principles of cancer therapy. In: Isselbacher KJ, Brauwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL. (eds) Harrison's Principles of Internal Medicine (13th edn). New York: McGraw-Hill, 1994: 1826-40.
63. Boddie AW, Briele H, Krementz ET. A phase I study of melphalan in 40 degrees C isolated limb perfusion using packed red blood cells and lactated Ringer's perfusate (abstract). Proc ASCO 1992; 11: 351.
64. Didolkar MS, Fitzpatrick JL, Jackson AJ, Johnston GS. Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma. Cancer 1986; 57: 1961-6.
65. Ghussen F, Nagel K, Groth W, Müller JM. Stützer H. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 1984; 200: 4-768.
66. Matsen FA. Compartmental syndrome: an unified concept. Clin Orthop Rel Res 1975; 113: 8-14.
67. Reneman RS. The anterior and lateral compartmental syndrome of the leg due to intensive use of muscles. Clin Orthop Rel Res 1975; 113: 69-79.
68. Fraker DL, Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In: DeVita VT. Hellman S. Rosenberg SA (eds) Important Advances in Oncology 1994. Philadelphia: JB Lippincott Company, 1994: 179-92.
69. Liénard D. Eggermont AMM. Schraffordt Koops H, et al. Isolated perfusion with high-dose tumor necrosis factor-alpha, interferon-gamma and melphalan for melanoma stage III: results of a multicenter pilot study. Melanoma Res 1994; 4 (Suppl. 1): 21-6.
70. Gérain J, Liénard D, Ewalenko P, Lejeune FJ. High serum levels of TNFα after its administration for isolation perfusion of the limbs. Cytokine 1992; 4: 585-91.
71. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995; 13: 264-73.
72. Swaak AJG, Liénard D, Schraffordt Koops H, Lejeune FJ, Eggermont AMM. Effects of recombinant tumor necrosis factor alpha (rTNFα) in cancer: observations of the acute phase protein reaction and immunoglobin synthesis after high dose rTNFα administration in isolated limb perfusions in cancer patients. Eur J Clin Inv 1993; 23: 812-8.